SB to market Magainin Cytolex topical antibiotic under $32.5 mil. agreement.
Executive Summary
SMITHKLINE BEECHAM TO MARKET MAGAININ CYTOLEX ANTIBIOTIC CREAM under an agreement worth up to $32.5 mil. announced Feb. 13. Cytolex (MSI-78) topical antibiotic cream is undergoing a second Phase III trial for the treatment of infection in diabetic foot ulcers. Magainin expects to complete the trial in the first quarter and to file the Cytolex NDA in the fourth quarter of 1997, the company said.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth